Aims

Liver disease is one of the leading causes of lost years of working life in Europe, second only to ischaemic heart disease. And, without a doubt, non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in our environment. Progress in the prevention and treatment of NAFLD is closely linked to the understanding of this disease from the pathophysiological and clinical point of view as a basis for a better definition of risk factors, the establishment of adequate predictors of disease progression, the definition of new biomarkers and the individualisation of therapy adjusted to the  characteristics of each patient.

Target Group

The programme is aimed at clinical, research and support staff with an interest in the field of the speciality, who wish to learn more about aspects related to research and precision medicine from experts.